Psychedelic combo trial aims to ease PTSD in veterans

NCT ID NCT06989957

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study at Johns Hopkins is testing whether giving both psilocybin and MDMA together is safe and can help reduce PTSD symptoms in military veterans. Forty veterans with PTSD will receive the drugs in a controlled setting. The study tracks side effects, suicidal thoughts, PTSD severity, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

psilocybin and MDMA

What this could lead to

If it works, this could point toward a new treatment option for PTSD that combines two psychedelic drugs.

What could go wrong

This is a very early Phase 1 trial with only 40 participants, so results may not apply widely. There are also risks like adverse events or worsening of symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTTRAUMATIC STRESS DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Johns Hopkins Center for Psychedelic and Consciousness Research

    RECRUITING

    Baltimore, Maryland, 21224, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••